Objective To investigate the clinical application of dabigatran etexilate in elderly patients with non-valvular atrial fibrillation.Methods Clinical materials of elderly non-valvular atri-al fibrillation patients with dabigatran etexilate in the Department of Cardiology of the Subei People's Hospital Affiliated to Yangzhou University from January 2021 to June 2022 were collected,and ac-cording to the relevant guidelines,clinical application,laboratory indicators and clinical outcomes were statistically analyzed.Results Among 150 patients,14 cases had no indications for medication and 12 cases had contraindication;93 cases had insufficient dosage,9 cases had excessive dosage,13 cases had unreasonable frequency of administration,and 20 cases had unreasonable conversion with other anticoagulant drugs.Laboratory indicators indicated a significant increase trend in activated partial prothrombin time(APTT)after 1 month,3 and 6 months of medication(P＜0.05).Clinical outcome showed that the incidence of ischemic stroke events was 3.33％(4/120),the incidence of massive bleeding was 1.67％(2/120),and the incidence of cerebral hemorrhage events was 0.83％(1/120).Conclusion It is common that clinical dosage of dabigatran etexilate in our hospital is in-sufficient.Pharmacists should pay attention to the standardized application of dabigatran etexilate in elderly patients.
关键词
达比加群酯/非瓣膜性心房颤动/老年患者/合理用药/抗凝治疗/不良反应
Key words
dabigatran etexilate/non-valvular atrial fibrillation/elderly patients/rational ad-ministration of drugs/anticoagulant therapy/adverse reactions
维普
万方数据